Cargando…

The clinical guiding value of a radiomics model for androgen deprivation therapy for prostate cancer

OBJECTIVE: Three models were used to evaluate prostate cancer after androgen deprivation therapy (ADT) and to determine the value of detecting residual lesions after treatment. METHODS: We retrospectively analysed patients with prostate cancer who received ADT from January 2018 to June 2019. Patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Na, Wang, Baoping, Ren, Jialiang, Wu, Hui, Gao, Yang, Liu, Aishi, Niu, Guangming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258766/ https://www.ncbi.nlm.nih.gov/pubmed/34187217 http://dx.doi.org/10.1177/03000605211014301

Ejemplares similares

Multiparameter MRI Radiomics Model Predicts Preoperative Peritoneal Carcinomatosis in Ovarian Cancer
por: Yu, Xiao Yu, et al.
Publicado: (2021)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2022)

Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2023)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy
por: WILSON, REBEKAH L., et al.
Publicado: (2021)

Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status
por: He, Jinlong, et al.
Publicado: (2022)

Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy
por: Saylor, Philip J., et al.
Publicado: (2009)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer
por: Al-Shamsi, Humaid O., et al.
Publicado: (2012)

Resistance Exercise Training Increases Muscle Mass and Strength in Prostate Cancer Patients on Androgen Deprivation Therapy
por: HOUBEN, LISANNE H. P., et al.
Publicado: (2023)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015)

AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
por: Sanguineti, G, et al.
Publicado: (2002)

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
por: Shiota, Masaki, et al.
Publicado: (2015)

Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer
por: Gilbert, Stephen E, et al.
Publicado: (2016)

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
por: Terrisse, Safae, et al.
Publicado: (2022)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
por: Parker, C C, et al.
Publicado: (2002)

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases
por: Varenhorst, Eberhard, et al.
Publicado: (2016)

Fasting Blood Glucose and Lipid Profile Alterations following Twelve-Month Androgen Deprivation Therapy in Men with Prostate Cancer
por: Sağlam, Hasan S., et al.
Publicado: (2012)

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
por: Braunstein, Lior Z., et al.
Publicado: (2014)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT Features Extracted from Different Radiomic Zones Predict Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer
por: Tran, Vuong Thuy, et al.
Publicado: (2022)

Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
por: Dong, Xin, et al.
Publicado: (2022)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_eglmcc3hlv5gnv0ondsbcsd7v4